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Abstract
Background: Rho iso-alpha acids (RIAA) from hops have been shown to have anti-inflammatory
properties. To understand the mechanisms, we evaluated the effect of RIAA in cell signaling
pathways and inflammatory markers using various in vitro models. We also investigated their
therapeutic effect in mice with collagen-induced arthritis.
Methods: The LPS-stimulated RAW 264.7 macrophages were used to evaluate the effect of RIAA
on the NF-κB and MAPK signaling pathways; phosphorylation of ERK1/2, p38 and JNK was assessed
by western blotting and NF-κB binding by electrophoretic mobility shift assays. Effect on the NF-
κB activity was evaluated by the luciferase reporter assays in LPS-stimulated RAW 264.7 cells. GSK-
3α/β kinase activity was measured in cell-free assays. The inhibitory effect of RIAA on inflammatory
markers was assessed by measuring nitric oxide in LPS-stimulated RAW 264.7 cells, RANKL-
mediated TRAP activity in transformed osteoclasts, and TNF-α/IL-1β-mediated MMP-13
expression in SW1353 cells. Mice with collagen-induced arthritis were fed with RIAA for 2 weeks.
Symptoms of joint swelling, arthritic index and joint damage were assessed.
Results: RIAA selectively inhibited the NF-κB pathway while having no effect on ERK1/2, p38 and
JNK phosphorylation in LPS-stimulated RAW 264.7 cells. RIAA also inhibited GSK-3α/β kinase
activity and GSK-3β dependent phosphorylation of β-catenin in RAW 264.7 cells. In addition, RIAA
inhibited NF-κB-mediated inflammatory markers in various cell models, including nitric oxide in
LPS-stimulated RAW 264.7 cells, RANKL-mediated TRAP activity in transformed osteoclasts, and
TNF-α/IL-1β-mediated MMP-13 expression in SW1353 human chondrosarcoma cells. Finally, in a
mouse model of collagen-induced arthritis, RIAA ameliorated joint damage as evidenced by
significant reduction of the arthritis index and histology score; at 250 mg/kg-body weight, RIAA had
efficacy similar to that of 20 mg/kg-body weight of celecoxib.
Conclusion: RIAA may have potential as an anti-inflammatory therapeutic.
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Background
The inflammatory markers such as prostaglandin (PG) E2,
nitric oxide (NO), tumor necrosis factor-α (TNF-α), and
interleukins (ILs) play important role in chronic inflam-
matory diseases. Inflammation is mediated by several
transcriptional factors, including NF-κB, CREB, C/EBPβ
and AP-1, through the activation of multiple signaling
pathways; for example, NF-κB, MAPK ERK1/2, p38 and
PI3K pathways (reviewed in [1]).
In the presence of a stimulus, such as lypopolysaccharide
(LPS), the innate immune response is triggered via activa-
tion of the NF-κB pathway: activation of IκB kinase (IKK)
complex leads to phosphorylation of IκB and causes the
degradation of the complex, which permits the dissocia-
tion and nuclear translocation of NF-κB p50/p65. NF-κB
in the nucleus binds to DNA and activates inflammatory
genes and proteins. Alternatively, independent of IKK acti-
vation, phosphorylation of NF-κB p65 at serine 468 by
glycogen synthase kinase (GSK)-3β also activates the NF-
κB pathway, and the inhibition of GSK-3β has been
shown to ameliorate inflammation [2,3]. In addition,
gene knockout mice of NF-κB p65 or GSK-3β showed sim-
ilar phenotype and embryonic lethality caused by liver
degeneration [4,5], suggesting that they share a common
pathway. Hence, the current development of compounds/
drugs to treat inflammatory diseases (e.g. rheumatoid
arthritis, or RA) has been targeting the GSK-3/NF-κB path-
way.
Rho iso-alpha acids (RIAA) are a modified extract from
hops (Humulus lupulus) that has self-affirmed GRAS (gen-
erally regarded as safe) status as determined by an expert
panel and used as flavoring/bittering agents in the brew-
ing industry throughout the globe. Our past research sug-
gested that RIAA had anti-inflammatory potential; RIAA
dose-dependently inhibited PGE2 production in LPS-stim-
ulated RAW 264.7 macrophages and reduced knee
arthritic pain in humans with no reported serious adverse
effects [6,7]. In addition, in contrast to nonsteroidal anti-
inflammatory drugs (NSAIDs), RIAA inhibited inducible
but not constitutive cyclooxygenase (COX)-2 in vitro; and
in human studies, RIAA showed no effect on fecal calpro-
tectin and urinary PGI2, markers used to assess gastroin-
testinal and cardiovascular complications [6].
Furthermore, animal oral toxicology data reveal that an
RIAA-containing product (45% RIAA of 250 mg/kg/day)
for 21 days showed no adverse effects in mice [8]. These
results indicate that RIAA have safer, therapeutic potential
to address inflammation.
To understand the anti-inflammatory mechanisms, we
evaluated the effects of RIAA in cell signaling pathways
and inflammatory markers using various in vitro models.
We also investigated the therapeutic effects of RIAA in
mice with collagen-induced arthritis (CIA).
Materials and methods
Materials
RIAA was supplied by Hopsteiner (New York, NY); the
chemical composition of RIAA was described in [6]. Phos-
pho-ERK1/2, phospho-p38, phospho-JNK, phospho-β-
catenin anti-bodies were purchased from Cell Signaling
Technology (Danvers, MA). SB216763 was purchased
from Biomol (Plymouth Meeting, PA). LPS (from E. coli),
anti-actin antibody, parthenolide and other analytical
grade chemicals were purchased from Sigma (St. Louis,
MO). Electrophoresis gels and reagents were purchased
from Bio-Rad (Hercules, CA).
Cell culture
RAW 264.7 macrophages were purchased from ATCC
(Manassas, VA) and maintained in Dulbecco's Modified
Eagle's Medium (DMEM) in the presence of 10% fetal
bovine serum (FBS), 100 U penicillin/ml and 100 μg
streptomycin/ml, according to manufacturer instructions.
All test compounds were dissolved in DMSO, then diluted
in serum-free media and used at a final concentration of
0.1% DMSO.
Electrophoretic mobility shift assays (EMSA)
RAW 264.7 cells were sub-cultured and grown overnight
in 6-well plates at a density of 2 × 106 cells per well, and
incubated in the absence or presence of RIAA for 1 h fol-
lowed by LPS (1 μg/ml) stimulation for 2 h. Nuclear
extract was prepared as previously described [9] with
modifications. Briefly, cells were lysed with lysis buffer
containing 10 mM Hepes-KOH (pH 7.9), 0.1% NP-40, 10
mM KCl, 1.5 mM MgCl2, and protease inhibitor cocktail
(Amersham Biosciences, Piscataway, NJ) for 15 min on ice
and centrifuged at 10,000× for 10 min. Cell pellet was
washed with the lysis buffer, resuspended in nuclear
extract buffer containing 20 mM Hepes-KOH, 25% glyc-
erol (v/v), 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA
and protease inhibitor cocktail, and sonicated (2 × 10 sec
at 60% power level). The samples were centrifuged at
10,000× for 10 min and the nuclear extract was stored at -
80°C until analysis. For DNA binding activity, 5 μg of the
nuclear extract was incubated with ~3 × 104  cpm of
[32P]ATP -labeled NF-κB consensus oligonucleotide (5'-
AGTTGAGGGGACTTTCCCAGGGC) at room temperature
for 20 min. This EMSA probe has been previously shown
to be specific for NF-κB [10]. Following electrophoresis at
on 5% nondenaturing acrylamide gel, the gel was dried
and exposed to X-ray film and developed by autoradiogra-
phy.
Western blot analysis
RAW 264.7 cells were grown overnight in 12-well plates at
a density of 106 cells per well, serum starved for 5 h, and
incubated with various concentrations of RIAA for 1 h.
Cells were washed with PBS and lysed in lysis buffer con-
taining 0.1% Triton X-100, 20 mM Tris (pH 8.0), 100 mMJournal of Inflammation 2009, 6:26 http://www.journal-inflammation.com/content/6/1/26
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KCl, 1 mM DTT, 1 mM PMSF and protease inhibitor cock-
tail. Total cell lysates were electrophoresed, and incubated
overnight at 4°C with primary antibodies of phospho β-
catenin (Ser33/37), phospho-ERK1/2 (Thr202/Tyr204),
phospho-p38 (Thr180/Tyr182) and phosphor-JNK
(Thr183/Tyr185). These antibodies have been shown pre-
viously to be specific [11]. Secondary antibody linked to
horseradish peroxidase (Amersham Biosciences) was
incubated for 1 h at room temperature, after which pro-
teins were visualized using the enhanced chemilumines-
cence (ECL) system from Pierce (Rockford, IL). For the
loading control, the membranes were stripped and the
blot analyzed by using anti-actin antibody.
NF-κB driven luciferase activity
RAW 264.7 cells were sub-cultured in 96-well plates at a
density of 7 × 104 cells per well and transiently transfected
using SuperFect transfection reagent with an NF-κB or
cAMP-responsive-element (CRE) firefly luciferase con-
struct (SuperArray, Frederick, MD). After 2 days, cells were
pre-incubated with various concentrations of RIAA or the
NF-κB inhibitor parthenolide (10 μM) for 1 h in serum-
free media, followed by 8 h LPS (1 μg/ml) stimulation.
Luciferase activity was measured using Dual-Luciferase®
Reporter Assay System (Promega, Madison, WI) per the
manufacturer's instructions. Transfection was normalized
with constitutively expressing Renilla luciferase.
Kinase assays
Kinase assays were performed at the Upstate Biotechnol-
ogy (Dundee, UK). Briefly, GSK-3α/β activity was meas-
ured in the absence or presence of RIAA. In a final reaction
volume of 25 μl the kinase of interest (5–10 mU) was
incubated with 20 μM peptide substrate (YRRAAVPP-
SPSLSRHSSPHQS(p)EDEEE), 10 mM MgAcetate and [γ-
33P-ATP] (specific activity approximately 500 cpm/mM) in
the presence of 8 mM MOPS (pH 7.0) and 0.2 mM EDTA.
The reaction was initiated by the addition of the 10 μM
MgATP mix. After 40 min of incubation at room tempera-
ture, the reaction was stopped by the addition of 5 μl of a
3% phosphoric acid solution. 10 μl of the reaction was
then spotted onto a P30 filtermat and washed 3 times for
5 min in 50 mM phosphoric acid and once in methanol
prior to drying and scintillation counting. Detailed proto-
cols are available online (at http://www.millipore.com/
drugdiscovery/dd3/assayprotocols).
Nitrite/Nitrate
RAW 264.7 cells were sub-cultured overnight in 96-well
plates at a density of 7 × 104 cells per well and incubated
with various concentrations of RIAA for 1 h in serum-free
media, followed by overnight LPS (1 μg/ml) stimulation.
Nitrate/nitrite levels in the medium were measured using
the Fluorometric Assay Kit (Cayman Chemical, Ann
Arbor, MI) per the manufacturer's instructions.
Osteoclastogenisis and tartrate-resistant acid 
phosphatase (TRAP) activity
RAW 264.7 cells were sub-cultured in 48-well plates at a
density of 7 × 104 cells per well and incubated with vari-
ous concentrations of RIAA in medium at a final concen-
tration of 0.1% DMSO. Following overnight incubation,
50 ng/ml of soluble receptor activator of NF-κB-ligand
(sRANKL) was added. After 2 days, medium and all rea-
gents were replaced and incubation was continued for 3
more days. Cells were washed with ice cold PBS, lysed in
150 μl of 0.2% Triton X-100 in PBS, and TRAP activity was
determined using a TRAP Kit from Sigma (Cat. #387A1).
Briefly, 100 μl lysate was added to 100 μl of TRAP solution
and incubated at 37°C for 1 h followed by measurement
of absorbance at 555 nm. Protein concentration was esti-
mated using BCA reagent (Bio-Rad) and final activity was
normalized for equal protein.
Chondrocytes and matrix metalloproteinase (MMP)-13 
expression
The human chondrosarcoma cell line SW1353 was pur-
chased from ATCC and maintained in L-15 medium in
the presence of 10% FBS, according to manufacturer
instructions. Cells were sub-cultured overnight in 96-well
plates at a density of 8 × 104 cells per well. Following 1 h
of incubation with various concentrations of RIAA, TNF-α
or IL-1β (10 ng/ml) was added for 20–24 h and MMP-13
levels measured in medium using an ELISA kit (Amer-
sham Biosciences), according to the manufacturer's
instructions.
Animal study
The study was performed at the Washington Biotechnol-
ogy, Inc. (Simpsonville, MD) laboratories with approved
standard protocol (CIA-MI). (i) Induction of collagen-
induced arthritis: 6.5 ml of bovine type II collagen was
emulsified with an equal volume of Complete Freund's
Adjuvant (CFA, Chondrex, Redmond, WA, 4 mg/ml).
Female DBA/1J mice (6–7 weeks) [2] were injected subcu-
taneously at the base of the tail with 50 μl of the emulsion
(containing 100 μg type II collagen), with a booster injec-
tion after 21 days. After 7 days, mice that developed arthri-
tis were used for the study. (ii) Experimental groups: Each
group consists of 10 animals for (1) vehicle treatment –
50 μl distilled water/CFA emulsion, (2) celecoxib – 20
mg/kg, (3–5) RIAA – 250, 50 and 10 mg/kg, respectively,
and (6) the "non-diseased" control. Test agents in 2%
Tweeen-80 were administered daily by gavage (10 ml/kg).
Treatment continued for 14 days and the arthritic index
determined every other day. (iii) Determination of the
arthritic index: Each paw was evaluated on the basis of a
4-point ordinal scale: 0 – no visible signs, 1 – edema/ery-
thema of a single joint or digit; 2 – edema/erythema of 2
joints; 3 – edema/erythema of > 2 joints; 4 – severe arthri-
tis of the entire paw and digits accompanied by ankylosisJournal of Inflammation 2009, 6:26 http://www.journal-inflammation.com/content/6/1/26
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of the ankle and limb deformity. The index was calculated
by summing from all four paws with a maximum score of
16. (iv) Histological evaluation: At day 42, mice were
euthanized. One limb from each mouse was removed and
preserved in 10% buffered formalin, decalcified, and sub-
sequently trimmed so as to render a longitudinal section
through the limb and digits. The specimens were proc-
essed, blocked, sectioned, stained with Haematoxylin and
Eosin for microscopic examination. Soft tissue, bone and
joint changes were evaluated using a standardized severity
Effect of RIAA on LPS-induced inflammatory signaling pathways in RAW 264.7 cells Figure 1
Effect of RIAA on LPS-induced inflammatory signaling pathways in RAW 264.7 cells. (A) Cells were incubated for 
1 h with RIAA (0, 10 and 20 μg/ml) followed by LPS stimulation (1 μg/ml) for 2 h. Nuclear extract were analyzed for NF-κB 
binding by EMSA. (B) Cells were pre-incubated with RIAA (5 and 20 μg/ml) for 1 h and stimulated with LPS (1 μg/ml) for 1 h. 
Cell lysates were analyzed for phosphorylation of ERK1/2, p38 and JNK using western blot. (C) Cells transiently transfected 
with NF-κB firefly luciferase construct were incubated with RIAA (1, 5 and 10 μg/ml) or NF-κB inhibitor parthenolide (10 μM) 
for 1 h followed by LPS (1 μg/ml) stimulation for 8 h. The luciferase activities were determined and normalized with Renilla 
expression, and expressed as fold change compared to vehicle control. Data shown is representative of the experiment 
repeated several times. (D) Cells transiently transfected with CRE firefly luciferase construct were incubated with RIAA (1, 5 
and 10 μg/ml) for 1 h followed by LPS (1 μg/ml) stimulation for 8 h. The luciferase activities were determined and corrected 
with Renilla expression, and expressed as fold change compared to vehicle control. Data shown is representative of the exper-
iment repeated several times.Journal of Inflammation 2009, 6:26 http://www.journal-inflammation.com/content/6/1/26
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score whereby 0 = not present, 1 = minimal, 2 = mild, 3 =
moderate and 4 = severe.
Statistical analysis
SAS 9.0 (Cary, NC) was used for the statistical analyses.
The in vitro data (NO inhibition, TRAP activity and MMP-
13 inhibition) and the in vivo data (arthritis index and
histological index) were analyzed using one-way ANOVA
with Dunnett's post-hoc multiple comparisons in which
the treatment groups were compared to the positive con-
trol; data are expressed as mean ± SEM. The significance
level was at 0.05. No statistical tests were performed on
data from a single experiment.
Results
Effects of RIAA on signaling pathways in LPS-stimulated 
RAW 264.7 macrophages
First, the effect of RIAA on NF-κB in vitro was investigated.
RAW 264.7 cells were treated with LPS alone (1 μg/ml) or
RIAA (10 and 20 μg/ml) followed by LPS incubation.
Nuclear extracts were then analyzed by EMSA. RIAA at 20
μg/ml inhibited NF-κB to its consensus sequence as evi-
denced by reduced band intensity (Fig. 1A, lane 4). Next,
the effect of RIAA on MAPK was investigated. Western blot
analysis of total extract showed that, in the presence or
absence of LPS stimulation, RIAA (5 and 20 μg/ml) had
no effects on phosphorylation of ERK1/2, p38 and JNK in
RAW 264.7 cells (Fig. 1B). Next, RAW cells were trans-
fected with either NF-κB or CRE firefly luciferase con-
struct, treated without or with RIAA (1, 5 and 10 μg/ml),
and followed by LPS (1 μg/ml) stimulation. The luciferase
reporter assays revealed that RIAA inhibited transactiva-
tion of NF-κB (Fig. 1C), but had no effects on that of CRE
(Fig. 1D).
Effects on the GSK-3 signaling pathway
GSK-3α/β kinase activities were evaluated in the absence
or presence of RIAA (1 – 50 μg/ml) in cell-free kinase
assays. We found that RIAA dose-dependently inhibited
both kinases (Fig. 2A and 2B). We also measured phos-
phorylation of β-catenin, a known GSK-3 substrate, in
RAW 264.7 cells by western blotting. Cells treated with
RIAA for 1 h inhibited β-catenin phosphorylation (Fig.
2C).
Effects on inflammatory markers associated with the NF-
κB pathway
We investigated whether RIAA affected various inflamma-
tory markers using established in vitro cell models
[6,12,13]. First, in LPS-stimulated RAW 264.7 cells we
found that RIAA dose-dependently inhibited NO levels,
particularly at 10 and 20 μg/ml (Fig. 3A). Second, in
RANKL-transformed osteoclasts/RAW cells, RIAA at 10
μg/ml inhibited TRAP activity (Fig. 3B). Third, in SW1353
cells, RIAA at 10 and 20 μg/ml inhibited TNF-α mediated
MMP-13 secretion in a dose-dependent manner (Fig. 3C),
and RIAA at 5, 10 and 20 μg/ml inhibited IL-1β mediated
MMP-13 secretion (Fig. 3D).
Inhibition on arthritis index in CIA model
Mice with CIA were orally fed 10, 50, or 250 mg/kg-body-
weight of RIAA, and symptoms of joint swelling were
measured daily for 14 days and the arthritic index was cal-
culated. We found that RIAA dose-dependently reduced
Effect of RIAA on the inhibition of GSK3 pathway Figure 2
Effect of RIAA on the inhibition of GSK3 pathway. (A) GSK-3α was incubated with RIAA (0, 5, 25 and 50 μg/ml) and the 
kinase activity was determined. Data represent 1 representative experiment and are expressed as % activity. (B) GSK-3β was 
incubated with RIAA (0, 1, 5, 25 and 50 μg/ml) and the kinase activity was determined. Data represent 1 representative exper-
iment and are expressed as % activity. (C) RAW 264.7 cells were incubated with RIAA (0, 1, 5, 10 and 20 μg/ml), or GSK-3 
inhibitors LiCl (10 mM) and SB216763 (10 μM) for 1 h. Cell lysates were analyzed for the inhibition of phosphorylation of β-
catenin by western blot.Journal of Inflammation 2009, 6:26 http://www.journal-inflammation.com/content/6/1/26
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the arthritis index, and at 250 mg/kg, their efficacy was
similar to that of 20 mg/kg of celecoxib, the positive con-
trol (Fig. 4A). Joints from the animals were also evaluated
histologically. RIAA at 250 mg/kg significantly reduced
the histological index, but not celecoxib (Fig. 4B). Analy-
ses of individual markers revealed that, compared to the
diseased controls, animals receiving RIAA (250 mg/kg)
showed significant reduction in joint destruction (1.90 ±
0.43 vs. 0.20 ± 0.20, P < 0.001), cartilage degradation
(2.65 ± 0.26 vs. 1.85 ± 0.15, P = 0.003) and bone erosion
(2.65 ± 0.15 vs. 1.75 ± 0.17, P = 0.002).
Discussion
Inflammatory diseases such as RA are predominantly
treated with NSAIDs or selective COX-2 inhibitors. Due to
their well-known adverse effects in the gastrointestinal
and cardiovascular systems when they are used long-term,
researchers have been seeking novel candidates with safer
Effect of RIAA on the inhibition of inflammatory markers Figure 3
Effect of RIAA on the inhibition of inflammatory markers. (A) RAW 264.7 cells were incubated with vehicle or RIAA 
(1, 5, 10 and 20 μg/ml) for 1 h and subsequently stimulated with LPS (1 μg/ml) overnight. Nitrite/nitrate levels were measured 
in the medium and expressed as % activity over LPS stimulation. Data represent mean ± SEM (n = 6). (B) RAW cells were pre-
treated with vehicle or RIAA (1, 5 and 10 μg/ml) overnight and stimulated with RANKL (50 ng/ml) for transformation to oste-
oclasts for 5 days. TRAP activity was measured in the cell lysate and expressed as % activity over RANKL stimulation. Data 
represent mean ± SEM (n = 6). (C) SW1353 cells were incubated with vehicle or RIAA (1, 5, 10 and 20 μg/ml) for 1 h and stim-
ulated with TNF-α (10 ng/ml) for 20–24 h. MMP-13 levels were measured in the medium and expressed as % activity over 
TNF-α stimulation. Data represent mean ± SEM (n = 5). *a significant difference (P < 0.05) in % activity compared to the 
respective positive control after Dunnett post-hoc adjustment. (D) Protocol same as (C) except IL-1β (10 ng/ml) was used 
instead of TNF-α. Data shown is that of a single experiment.Journal of Inflammation 2009, 6:26 http://www.journal-inflammation.com/content/6/1/26
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modes of action. We found RIAA to be a promising anti-
inflammatory candidate as it did not negatively impact
gastrointestinal and cardiovascular biomarkers (e.g. fecal
calprotectin and PGI-M/TXB2 ratio) commonly associated
with NSAIDs [6]. To gain further understanding of RIAA's
anti-inflammatory mechanism (s), we evaluated its effects
on cell signaling pathways and in vitro inflammatory
markers. We examined the effects of RIAA on NF-κB and
MAPK in RAW 264.7 macrophages because these path-
ways activate transcriptional and post-transcriptional fac-
tors that upregulate pro-inflammatory genes, enzymes
and cytokines [1,14,15]. We found that RIAA inhibited
the LPS-activated nuclear NF-κB binding to its consensus
sequence, which indicated a reduction in nuclear abun-
dance of NF-κB (Fig. 1A). In addition, RIAA dose-depend-
ently reduced the LPS-induced-transcriptional activity of
NF-κB (Fig. 1C). On the other hand, RIAA did not affect
the phosphorylation of ERK1/2, p38 and JNK in RAW
cells (Fig. 1B), nor the transactivation of CRE (Fig. 1D), a
known transcriptional factor regulated by MAPK in LPS-
activated macrophages [16]. The data demonstrated that
RIAA specifically inhibited NF-κB signaling pathway but
not MAPK pathways.
In general, the activation of NF-κB is regulated at several
levels, including IKK-mediated IκB degradation and
nuclear translocation and DNA binding. During our
screening we found that RIAA did not inhibit IKK (data
now shown). Alternatively, post-translational modifica-
tion of NF-κB-p65 regulates the function of NF-κB
[3,17,18]; and through the p65 subunit, GSK-3 has been
shown to regulate the production of pro-inflammatory
cytokines. Therefore, we investigated the effects of RIAA
on the GSK-3 signaling pathway. Both GSK-3α and GSK-
3β were inhibited by RIAA (Fig. 2A and 2B), and phos-
phorylation of a known GSK-3 substrate, β-catenin, was
inhibited by RIAA in RAW 264.7 cells (Fig. 2C). This
mode of action is similar to a known GSK-3 inhibitor,
SB216763, which also inhibited β-catenin [19]. It has
been shown that β-catenin plays a significant anti-inflam-
matory role by reducing NF-κB activity [20]. Therefore,
our data suggested that the anti-inflammatory mechanism
Effect of RIAA in mice model of CIA Figure 4
Effect of RIAA in mice model of CIA. The DBA/1J mice were injected intradermally with 100 μg of bovine type II collagen. 
After 21 days the mice were given a booster dose. CIA was fully developed at day 28 when treatments initiated and continued 
for the next 14 days. The arthritis index was assessed every other day. (A) The mean arthritis index for 3 RIAA treatment 
groups (10, 50 and 250 mg/kg body weight), celecoxib-treated group (20 mg/kg body weight) and the vehicle-treated control 
group. Day 42 data are expressed as mean ± SEM. Mice in the non-diseased group had an arthritis index of 0 throughout the 
experiment and therefore the data points were not displayed. (B) After evaluation of the arthritis index was completed at day 
42, mice were anesthetized, and a histological examination was performed in 3 RIAA treatment groups, celecoxib-treated 
group and the vehicle-treated group (mean ± SEM). *a significant difference (P < 0.05) in histology score compared to diseased 
control after Dunnett post-hoc adjustment.Journal of Inflammation 2009, 6:26 http://www.journal-inflammation.com/content/6/1/26
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of RIAA involves the inhibition of GSK-3/NF-κB pathway.
Future assessment of the inhibition of β-catenin phospho-
rylation in vivo will further strengthen our in vitro find-
ing.
We proceeded to investigate whether RIAA affected NF-
κB-mediated pro-inflammatory mediators in various in
vitro models, and found that it inhibited NO in LPS-stim-
ulated RAW 264.7 cells; RANKL-mediated TRAP activity in
transformed osteoclasts; and TNF-α/IL-1β-mediated
MMP-13 expression in SW1353 human chondrosarcoma
cells. It has been demonstrated that NO is involved in the
pathogenesis of arthritis [21,22]; enhanced TRAP activity
of osteoclasts increases bone resorption and contributes
to bone loss [23]; and IL-1/TNF-α stimulate chondrocytes
to increase production of MMPs and other degradative
products [24-26]. These mediators cause bone erosion
and cartilage degradation, and result in joint damage in
RA [27]. Interventions targeting one or more of these
mediators have been reported to reduce inflammation
and degree of severity of RA, osteoarthritis and osteoporo-
sis [23-25]; therefore, we tested the therapeutic effect of
RIAA in mice with CIA. Two weeks of oral administration
of RIAA at 250 mg/kg-body weight ameliorated joint
damage in these mice as evidenced by significant reduc-
tions in the arthritis index and histology score. We found
that the efficacy in reducing the arthritis index at this dose
was similar to that of 20 mg/kg-body weight of celecoxib.
Interestingly, however, celecoxib did not significantly
reduce the histology score. This is likely due to the fact
that celecoxib inhibits COX-2-mediated PGE2 synthesis
evidenced by the reduced arthritis index, but does not
inhibit NF-κB, an important mediator for bone and carti-
lage degradation.
Kinase inhibitors have shown beneficial effects in preclin-
ical or clinical trials or in animal disease models for the
treatment of cancer and autoimmune diseases [19,28,29].
For instance, GSK-3β inhibitors TDZD-8 and SB216763
reduced NF-κB mediated inflammation in rats with endo-
toxemia, and protected tissue damage in CIA mice. Our
data demonstrated that RIAA inhibited GSK-3β/NF-κB
mediated signaling pathways and inflammation, and
reduced RA symptoms in CIA mice, suggesting that RIAA
may have potential as an anti-inflammatory therapeutic.
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